Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-11
2011-01-11
Cook, Lisa V (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C436S501000, C436S506000, C436S518000, C422S050000, C422S067000, C530S300000, C530S350000, C424S009100
Reexamination Certificate
active
07867724
ABSTRACT:
Hypoxia, a state of lower than normal tissue oxygen tension, has recently been implicated in a host of human diseases, including cancer, heart disease, and neurological disorders. Novel associations between p97 and other proteins, including UBX-domain-containing proteins (UBX-polypeptides), HIF1α, and a variety of E3 ligases are provided herein. The disclosure provides complexes comprising UBX-domain-containing polypeptides (UBX-polypeptides) and other polypeptides involved in the degradation of ubiquitinated proteins. In addition, the disclosure provides uses for active agents that modulate protein-protein complex formation between an UBX-polypeptide and its complementary-binding substrate. For example, the disclosure provides methods for treating or preventing hypoxia-related disorders or conditions in a patient or a cell by administration of an active agent that modulates the activity of an UBX-polypeptide and/or its complementary binding-substrate. Furthermore, the disclosure provides uses for active agents that modulate HIF1α activity; such agents may be used to modulate processes that are regulated by HIF1α. The disclosure also provides many screening assays to identify test agents that modulate complex formation between an UBX-polypeptide and its complementary-binding substrate or methods for evaluating modes of action and/or effects of active agents that have already been identified as modulators of an UBX-polypeptide and/or its complementary-binding substrate.
REFERENCES:
Alexandru et al., UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover.Cell. 134(5): 804-816. (2008).
Bruderer et al., The AAA ATPase p97/VCP interacts with its alternative co-factors, Ufd1-Npl4 and p47, through a common bipartite binding mechanism.J Biol Chem.279:49609-49616. (2004).
Ghislain et al., Cdc48p interacts with Ufd3p, a WD repeat protein required for ubiquitin-mediated proteolysis inSaccharomyces cerevisiae. Embo J.15:4884-4899. (1996).
Graumann et al., Applicability of tandem affinity purification MudPIT to pathway proteomics in yeast.Mol Cell Proteomics. 3:226-237. (2004).
Hurley et al., Ubiquitin-binding domains.Biochem J.399:361-372. (2006).
Ivan et al., The von Hippel-Lindau tumor suppressor protein.Curr Opin Genet Dev.11:27-34. (2001).
Kondo et al., p47 is a cofactor for p97-mediated membrane fusion.Nature. 388:75-78. (1997).
Link et al., Direct analysis of protein complexes using mass spectrometry.Nat Biotechnol.17:676-682. (1999).
Meyer et al., A complex of mammalian ufd1 and npl4 links the AAA-ATPase, p97, to ubiquitin and nuclear transport pathways.Embo J.19:2181-2192. (2000).
Meyer et al., Direct binding of ubiquitin conjugates by the mammalian p97 adaptor complexes, p47 and Ufd1-Npl4.Embo J.21:5645-5652. (2002).
Park et al., Ufd1 exhibits the AAA-ATPase fold with two distinct ubiquitin interaction sites.Structure. 13:995-1005. (2005).
Rape et al., Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone.Cell. 107:667-677. (2001).
Richly et al., A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting.Cell. 120:73-84. (2005).
Rouiller et al., Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle.Nat Struct Biol.9:950-957. (2002).
Rumpf et al., Functional division of substrate processing cofactors of the ubiquitin-selective Cdc48 chaperone.Mol Cell.21:261-269. (2006).
Ryu et al., Binding surface mapping of intra- and interdomain interactions among hHR23B, ubiquitin, and polyubiquitin binding site 2 of S5a.J Biol Chem.278:36621-36627. (2003).
Schuberth et al., Membrane-bound Ubx2 recruits Cdc48 to ubiquitin ligases and their substrates to ensure efficient ER-associated protein degradation.Nat Cell Biol.7:999-1006. (2005).
Shcherbik et al., Cdc48pNPl4p/Ufd1pbinds and segregates membrane-anchored/tethered complexes via a polyubiquitin signal present on the anchors.Mol Cell.25:385-397. (2007).
Uchiyama et al. VCIP135, a novel essential factor for p97/p47-mediated membrane fusion, is required for Golgi and ER assembly in vivo.J Cell Biol.159:855-866. (2002).
Wang et al., VCIP135 acts as a deubiquitinating enzyme during p97-p47-mediated reassembly of mitotic Golgi fragments.J Cell Biol.164:973-978. (2004).
Ye Y. Diverse functions with a common regulator: Ubiquitin takes command of an AAA ATPase.J Struct Biol.(2006).
Ye et al., The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol.Nature. 414:652-656. (2001).
Ye et al., Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains.J Cell Biol.162:71-84. (2003).
Yuan et al., Solution structure and interaction surface of the C-terminal domain from p47: a major p97-cofactor involved in SNARE disassembly.J Mol Biol.311:255-263. (2001).
Zhong et al., AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation.J Biol Chem.279:45676-45684. (2004).
Alexandru Gabriela
Deshaies Raymond
Graumann Johannes
California Institute of Technology
Cook Lisa V
Ropes & Gray LLP
LandOfFree
Compositions and method of treating hypoxia-associated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and method of treating hypoxia-associated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and method of treating hypoxia-associated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664294